Description
Our research integrates medicinal chemistry, neuropharmacology, computational chemistry and molecular biology not only to understand the mechanism of action of novel CNS active molecules but also to advance promising leads to preclinical studies. We focus on discovery of novel CNS drugs to explore their potential therapeutic applications in several neuro-disorders like Parkinson’s disease (PD) and Alzheimer's disease, depression and drug addiction. Specifically, novel molecules which are designed through rational drug design and computational studies, are being developed routinely to target monoamine transporters and receptors systems either selectively or non-selectively to produce desired pharmacological response. In the neurodegeneration area we target pathogenic proteins like alpha synuclein and amyloid beta by small molecules to reduce the toxicities implicated in these diseases. Cell culture work are being carried out routinely to mimic disease models to test potential therapeutics developed in our laboratory